Home | Genmab
Mar 12, 2025 · Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases. As a leading international biotechnology company, we believe in …
Genmab Completes Acquisition of ProfoundBio - Genmab A/S
May 21, 2024 · Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash; Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel …
ProfoundBio | Piper Sandler
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological ...
Genmab to Broaden and Strengthen Oncology Portfolio with
Apr 3, 2024 · ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer...
Genmab acquires ProfoundBio in $1.8bn deal - Pharmaceutical …
May 22, 2024 · Genmab has concluded the previously announced acquisition of clinical-stage biotechnology company ProfoundBio in a $1.8bn cash transaction. ProfoundBio specialises in the development of antibody-drug conjugates (ADCs) and technologies for cancer treatment.
Biotech giant Genmab to acquire Seattle company ProfoundBio ... - GeekWire
Apr 3, 2024 · ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.8 billion all-cash deal...
ProfoundBio Raises $112 Million in Oversubscribed Series B …
SEATTLE, Feb. 13, 2024 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer, today announced an...
The morning after ProfoundBio | ApexOnco - Clinical Trials news …
Nov 8, 2024 · Seven months after shelling out $1.8bn for the ADC specialist ProfoundBio, Genmab has quietly revealed the R&D cuts it's now making to help balance the books. The biggest retreat is from taking Tivdak into head and neck cancer, and also gone are three of Genmab's phase 1 projects.
ADC startup ProfoundBio, led by Seagen veterans, raises $112M
Feb 13, 2024 · ADC startup ProfoundBio, led by Seagen veterans, raises $112M The startup is developing a competitor to the ovarian cancer drug Elahere, the focus of AbbVie’s $10 billion buyout of ImmunoGen last year.
Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio
Apr 3, 2024 · Danish drugmaker Genmab A/S (GMAB) said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio Inc. for $1.8 billion in cash as it expands its pipeline of cancer treatments.